IP Group PLC Istesso starts Phase 2b trial of MBS2320
August 31 2022 - 2:51AM
RNS Non-Regulatory
TIDMIPO
IP Group PLC
31 August 2022
FOR RELEASE ON 31 August 2022
IP Group plc - Portfolio company Istesso announces initiation of
Phase 2b trial of lead drug MBS2320
MBS2320 administered to participants with moderate-to-severe
rheumatoid arthritis
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which
develops world-changing science and technology businesses across
life sciences, technology and cleantech , notes that portfolio
company Istesso Ltd ("Istesso" or "the Company"), the
immunometabolism drug discovery and development company, has
announced the initiation of its Phase 2b trial of MBS2320, its lead
drug in rheumatoid arthritis, with the first patients now
dosed.
MBS2320 is a first-in-class investigational drug which reduces
inflammation and supports the remodelling of damaged tissue. This
dual mode-of-action enables MBS2320 to offer the unique potential
to reverse underlying pathology in bone and joints. Rheumatoid
Arthritis is a chronic, progressive, and disabling auto-immune
disease affecting one per cent of the global population, 165
million people worldwide.
The trial is a phase 2b randomized, multi-centre, double-blind
parallel group, placebo-controlled trial investigating the efficacy
and safety of multiple doses of the metabolic reprogramming agent
MBS2320. The study will enrol patients with Rheumatoid Arthritis
who have had an inadequate response to methotrexate. The primary
endpoint is the proportion of subjects achieving American College
of Rheumatology 20% (ACR20). The study will consist of a
twelve-week treatment period and will enrol subjects in multiple
countries in Europe and Latin America. Istesso expects results from
the study in 2024.
Sam Williams, Managing Partner, IP Group Life Sciences, and
Istesso Chairman, said: "This marks an important milestone for both
Istesso and IP Group. IP Group has been the majority shareholder in
Istesso for more than a decade and this news validates the Group's
long-term approach to supporting portfolio companies, technologies
and products that have the potential to change people's lives for
the better. IP Group fully supports Istesso's ambition to bring
MBS2320 to a range of patients who are inadequately served by
current treatments for rheumatoid arthritis and we look forward to
the data from this study in a couple of years' time."
IP Group has an undiluted holding of 56% in Istesso.
For more information, please contact:
IP Group plc www.ipgroupplc.com
+44 (0) 20 7444 0062/+44 (0)
Liz Vaughan-Adams, Communications 7967 312125
Charlotte Street Partners
David Gaffney +44 (0) 7854 609998
Andrew Wilson +44 (0) 7810 636995
Notes for editors
About IP Group
IP Group develops world-changing science and technology
businesses across life sciences, technology and cleantech (through
Kiko Ventures). The Group has a strong track record of success,
having been the founder investor in a number of high-profile
companies including Oxford Nanopore Technologies plc, and has one
of the most exciting portfolios of high-growth businesses in
Europe. The Group also owns Parkwalk, the UK's largest growth EIS
fund manager which backs world-changing technologies emerging from
the UK's leading universities and research institutions. IP Group
is listed on the Main Market of the London Stock Exchange under the
code IPO.
For more information, please visit our website at
www.ipgroupplc.com .
About Istesso
Istesso is a clinical-stage biopharmaceutical company,
developing novel drug candidates which reprogramme immune cell
metabolism to treat autoimmune and inflammatory conditions.
Istesso's products have applications in conditions such as
Rheumatoid Arthritis, Multiple Sclerosis and Cancer.
About MBS2320
MBS2320 is an investigational, first-in-class metabolic
reprogramming agent. Its unique dual mode of action, reducing
inflammation and supporting the remodelling of tissue damage gives
MBS2320 the potential to both control the disease symptoms and
resolve the underlying pathology across multiple disease
indications including RA and other autoimmune diseases.
About rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, progressive, and
disabling auto-immune disease affecting one per cent of the global
population, or 165 million people worldwide. Unchecked, RA can
progress very rapidly, causing swelling and damaging cartilage and
bone around the joints and cause severe disability. A number of
treatments are available for the conditions, but these are
associated with increased infection rates, and for some classes, a
risk of major cardiovascular events. In addition, a large
proportion of patients fail to respond, or experience ongoing
symptoms such as pain and flare, and continue to suffer from bone
erosions.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKDBQOBKKCFN
(END) Dow Jones Newswires
August 31, 2022 03:51 ET (07:51 GMT)
Ip (LSE:IPO)
Historical Stock Chart
From Apr 2024 to May 2024
Ip (LSE:IPO)
Historical Stock Chart
From May 2023 to May 2024